Cipla has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market.
Cipla Ltd, a homegrown pharma major, has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for Indian market from Novartis, stated by Cipla on Monday. Â However, the acquisition amount has not been disclosed.
















